Gene therapy of established medullary thyroid carcinoma with herpes simplex vital thymidine kinase in a rat tumor model: Relationship of bystander effect and antitumor efficacy

Thyroid

Volumn 10, Issue 4, 2000, Pages 313-319

  Zhang, Rusheng ^a   DeGroot, Leslie J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; THYMIDINE KINASE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL KILLING; CONTROLLED STUDY; DRUG EFFICACY; GENE EXPRESSION; GENE THERAPY; GENETIC TRANSDUCTION; HERPES SIMPLEX VIRUS; NONHUMAN; PRIORITY JOURNAL; RAT; THYROID MEDULLARY CARCINOMA; TUMOR GROWTH;

EID: 0034018399     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2000.10.313     Document Type: Article

References (36)

1. Marcel T, Grausz JD 1997 The TMC worldwide gene therapy enrollment report, end 1996. Human Gene Ther 8: 775-800.
2. Blaese RM, Ishii-Morita H, Mullen C, Ramsey J, Ram Z, Olddfield E, Culver K 1994 In situ delivery of suicide genes for cancer treatment. Eur J Cancer 30A:1190-1193.
3. Moolten F 1986 Tumor chemosensitivity conferred by inserted herpes kinase genes: Paradigm for a prospective cancer control strategy. Cancer Res 46:5276-5281.
4. Wygoda MR, Wilson MR, Davis MA, Trosko JE, Rehemtulla A 1997 Protection of herpes simplex virus thymidine kinase-transduced cells from ganciclovir-mediated cytotoxicity by bystander cells: the good samaritan effect. Cancer Res 57: 1699-1703.
5. Yang L, Chiang Y, Lenz H-J, Danenberg K-D, Spears CP, Gordon EM, Anderson WF, Parekh D 1998 Intercellular communication mediates the bystander effect during herpes simplex thymidine kinase/ganciclovir-based gene therapy of human gastrointestinal tumor cells. Human Gene Ther 9: 719-728.
6. Ishii-Morita H, Agbaria R, Mullen CA, Hirano H, Koeplin DA, Ram Z, Oldfield EH, Johns DG, Blaese RM 1997 Mechanism of 'bystander effect' killing in the herpes simplex thymidine kinase gene therapy model of cancer treatment. Gene Ther 4:244-251.
7. Hooper ML, Subak-Sharpe JH 1981 Metabolic cooperation between cells. Int Rev Cytol 69:45-104.
8. Trosko JW, Madhukar BV, Chang CC 1993 Endogenous and exogenous modulation of gap junctional intercellular communication: Toxicological and pharmacological implications. Life Sci 53:1-19.
9. Wolburg H, Rohlmann A 1995 Structure-function relationship in gap junctions. Int Rev Cytol 157:315-371.
10. Pitts JD 1994 Cancer gene therapy: A bystander effect using the gap junctional pathway. Mol Carcinog 11:127-130.
11. Goldberg G, Bertram JS 1993 In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res 53:83-88.
12. Colombo BM, Beneddetti S, Ottolenghi S, Mora M, Polio B, Poli G, Finocchiaro G 1995 The "bystander effect": Association of U-87 cell death with ganciclovir-mediated apoptosis of nearby cells and lack of effect in athymic mice. Human Gene Ther 6:763-772.
13. Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL 1993 The "bystander effect": Tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 53:5274-5283.
14. Moolten FL 1994 Drug sensitivity ("suicide") genes for selective cancer chemotherapy. Cancer Gene Ther 1:279-287.
15. Caruso M, Panis Y, Gagandeep S, Houssin D, Salzmann JL, Klatzmann D 1993 Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc Natl Acad Sci USA 90:7024-7028.
16. Freeman SM, Ramesh R, Marrogi AJ 1997 Immune system in suicide-gene therapy. Lancet 349:2-3.
17. Gagandeep S, Brew R, Green B, Christmas SE, Klatzmann D, Poston GJ, Kinsella AR 1996 Prodrug-activated gene therapy: Involvement of an immunological component in the "bystander effect". Cancer Gene Ther 3:83-88.
18. Sturtz FG, Waddell K, Shulok J, Chen X, Caruso M, Sanson M, Snodgrass HR, Platika D 1997 Variable efficiency of the thymidine kinase/ganciclovir system in human glioblastoma cell lines: Implications for gene therapy. Human Gene Ther 8:1945-1953.
19. Graham FL, Van Der Eb EJ 1973 A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 52:456-167.
20. Graham FL, Simley J, Russel WC, Naim R 1977 Characterization of a human cell line transformed by DNA from human adenovirus type 5. J Gene Viol 36:59-72.
21. Zhang R, Minemura K, DeGroot LJ. 1998 Immunotherapy for medullary thyroid carcinoma by a replication-defective adenovirus transducing murine interleukin-2 Endocrinology 139:601-608.
22. Touraine RL, Ishii-Morita H, Ramsey WJ, Blaese RM 1998 The bystander effect in the HSVtk/ganciclovir system and its relationship to gap junctional communication. Gene Ther 5:1705-1711.
23. Hwang HC, Smythe WR, Elshami AA, Kucharczuk JC, Amin KM, Williams JP, Litzky LA, Kaiser LR, Albelda SM 1995 Gene therapy using adenovirus carrying the herpes simplex-thymidine kinase gene to treat in vivo models of human malignant mesothelioma and lung cancer. Am J Respir Cell Mol Biol 13:7-16.
24. Kaneko S, Hallenbeck P, Kotani T, Nakabayashi H, McGarrity G, Tamaoki T, Anderson WF, Chiang YL 1995 Adenovirus-mediated gene therapy of hepatocellular carcinoma using cancer-specific gene expression. Cancer Res 55:5283-5287.
25. Sterman DH, Treat J, Litzky LA, Amin KM, Coonrod L, Molson JM, Albelda SM, Kaiser LR 1998 Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: Results of a phase I clinical trial in malignant mesothelioma. Human Gene Ther 9:1083-1092.
26. Mullen CA, Anderson L, Woods K, Nishino M, and Petropoulos D 1998 Ganciclovir chemoablation of herpes thymidine kinase suicide gene-modified tumors produces rumor necrosis and induces systemic immune responses. Human Gene Ther 9:2019-2030.
27. Nishihara E, Nagayama Y, Mawatari F, Tanaka K, Namba H, Niwa M, Yamashita S 1997 Retrovirus-mediated herpes simplex virus thymidine kinase gene transduction renders human thyroid carcinoma cell lines sensitive to ganciclovir and radiation in vitro and in vivo. Endocrinology 138:4577-4583.
28. Holder JW, Elmore E, Battett JC 1993 Gap junction function and cancer. Cancer Res 53:3475-3485.
29. Hotz-Wagenblatt A, Shalloway D 1993 Gap junctional communication and neoplastic transformation. Crit Rev Oncol 4:541-558.
30. Biw L, Parysek LM, Warnick R, Stambrook P 1993 In vivo evidence that metabolic cooperation is responsible for the bystander effect observed with HSV-TK retroviral gene therapy. Hum Gene Ther 4:725-731.
31. Mesnil M, Piccoli C, Tirary G, Willelke K and Yamasaki H 1996 Bystander killing of cancers by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc Natl Acad Sci USA 93:1831-1835.
32. Anderson LM, Swaminathan S, Zackon I, Tajuddin A-K, Thimmapaya B, Weitzman SA 1999 Adenovirus-mediated tissue-targeted expression of the HSVtk gene for the treatment of breast cancer. Gene Ther 6:854-864.
33. Kaneko S, Hallenbech P, Kotani T, Nakabayashi H, McGarrity G, Tamaoki T, Andeson WF, Chiang YL 1995 Adenovirus-mediated gene therapy of hepatocellular carcinoma using cancer-specific gene expression. Cancer Res 55:5283-5287.
34. Kanai F, Shiratori Y, Yoshida Y, Wakimoto H, Hamada H, Kanegae Y, Saito I, Nakabayashi H, Tamaoki T, Tanaka T, Lan KH, Kato N, Shiina S, Omata M 1996 Gene therapy for a-fetoprotein-producing human hepatoma cells by adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene. Hepatology 23:1359-1368.
35. Minemura K, Zhang R, DeGroot LJ 1998 Cell specific adenovirus gene therapy for medullary thyroid carcinoma [abstract]. In Proceedings of American Thyroid Association Annual Meeting. p45.
36. Zhang R, Straus FH, DeGroot J 2000 An adenoviral vector transducing tissue specific expression of thymidine kinase under the control of thyroglobulin promoter has high specificity and low toxicity in gene therapy. Clinical Endocrinology (in press).